• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Keystone Nano launches clinical trial for NanoLiposome cancer therapy

April 7, 2017 By Sarah Faulkner

Keystone Nano launches clinical trial for NanoLiposome cancer therapyKeystone Nano said today that it has begun clinical testing for its ceramide NanoLiposome cancer therapy. The Phase I trial plans to evaluate the company’s NanoLiposome as a targeted treatment for solid tumors.

Ceramide is a lipid that has demonstrated efficacy in liver cancer, breast cancer, leukemia and pancreatic cancer. Preclinical evidence has shown that the NanoLiposome is an effective delivery system for the bioactive compound, targeting cancer cells and ignoring healthy cells, according to the State College, Penn.-based company.

Keystone reported that the Phase I trial will recruit patients with solid tumors to establish dosing and safety, while the Phase II study will focus on liver cancer.

“I am very pleased this has reached the clinic.  Primary liver cancer is a devastating disease with incredibly poor outcomes and very few treatment options,” Keystone Nano’s chief medical officer Mark Kester said in prepared remarks.  “Ceramide NanoLiposome offers the potential to increase treatment options for these patients.”

“This is the first step in achieving one of the primary goals of Keystone Nano, to apply nanotechnology to create new therapeutic opportunities that cannot be pursued without our novel nanoscale platforms,” chief science officer James Adair added.

In January, Keystone Nano won orphan drug status for the treatment of liver cancer with ceramides.

Filed Under: Clinical Trials, Featured, Nanoparticles, Oncology, Wall Street Beat Tagged With: Keystone Nano

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS